ADAPT trial update: NSAIDs in AD


The Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) was launched a decade ago to determine if an NSAID (naproxen 220 mg BID or celecoxib 200 mg BID) could delay the onset of AD (ADAPT Research Group et al. Alzheimers Dement 2009; 5: 93-104; free full text at The trial was suspended in 2004 following the finding from the Adenoma Prevention with Celecoxib (APC) trial of an increased cardiovascular risk with celecoxib (Solomon et al. N Engl J Med 2005; 352: 1071-1080; free full text at

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page